Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Microsoft brings machine learning to genetics collaboration

Will work with Adaptive Biotechnologies on the human immune system

Genetic sequencing

Microsoft has teamed up with Seattle-based sequencing company Adaptive Biotechnologies to map the genetics of the human immune system.

The work aims to aid the early detection of diseases, particularly cancer, allowing them to be more effectively treated.

The IT giant will bring machine learning and cloud computing capabilities, with Adaptive contributing its immune sequencing technologies.

The deal, which will see Microsoft invest in Adaptive, falls within the firm’s Healthcare NExT initiative which was launched last year to accelerate healthcare innovation by applying artificial intelligence and cloud computing.

Peter Lee, corporate VP, AI and research at Microsoft, said: “We are very excited and inspired by our collaboration with Adaptive Biotechnologies, as it clearly advances our mission to use cloud and AI technologies to transform healthcare and improve the lives of people around the world.

The two companies hope to translate the immune system’s genetic code into simple blood-based diagnostics that can be made broadly accessible to people around the world.

Chad Robins, Adaptive’s president, CEO and co-founder, said: “Some conditions like cancer or autoimmune disorders can be difficult to diagnose, but this universal map of the immune system will enable earlier and more accurate diagnosis of disease, potentially helping physicians to connect the dots to understand the relationship between disease states and eventually lead to a better understanding of overall human health.”

31st January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics